Your browser is no longer supported. Please, upgrade your browser.
SHPG Shire plc daily Stock Chart
Shire plc
Index- P/E24.92 EPS (ttm)6.78 Insider Own0.10% Shs Outstand307.15M Perf Week0.26%
Market Cap51.89B Forward P/E10.45 EPS next Y16.17 Insider Trans0.00% Shs Float303.22M Perf Month2.79%
Income2.06B PEG4.79 EPS next Q3.65 Inst Own20.50% Short Float0.49% Perf Quarter33.38%
Sales15.35B P/S3.38 EPS this Y160.00% Inst Trans-1.57% Short Ratio0.98 Perf Half Y16.82%
Book/sh123.36 P/B1.37 EPS next Y6.30% ROA6.60% Target Price201.83 Perf Year-10.67%
Cash/sh1.09 P/C154.90 EPS next 5Y5.20% ROE12.90% 52W Range123.73 - 190.37 Perf YTD8.92%
Dividend1.05 P/FCF- EPS past 5Y7.50% ROI4.30% 52W High-11.25% Beta1.32
Dividend %0.62% Quick Ratio0.70 Sales past 5Y27.30% Gross Margin70.70% 52W Low36.55% ATR4.07
Employees23044 Current Ratio1.10 Sales Q/Q5.40% Oper. Margin17.30% RSI (14)65.97 Volatility1.41% 1.87%
OptionableYes Debt/Eq0.50 EPS Q/Q61.30% Profit Margin29.00% Rel Volume0.49 Prev Close168.95
ShortableYes LT Debt/Eq0.45 EarningsApr 26 BMO Payout6.90% Avg Volume1.51M Price168.95
Recom1.70 SMA203.08% SMA5010.82% SMA20014.24% Volume0 Change0.00%
May-11-18Resumed Kepler Buy
Feb-20-18Downgrade JP Morgan Overweight → Neutral
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $201 → $181
Feb-14-18Upgrade Bernstein Mkt Perform → Outperform
Dec-20-17Downgrade Liberum Buy → Hold
Nov-14-17Upgrade Liberum Hold → Buy
Oct-19-17Initiated FBR & Co. Buy $201
Oct-11-17Reiterated RBC Capital Mkts Outperform $213
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
May-22-18 07:01AM  Shire announces new hypoparathyroidism data at the 2018 European Congress of Endocrinology GlobeNewswire
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
May-21-18 04:51PM  Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business Investor's Business Daily
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
May-20-18 10:42PM  [$$] Takeda says Shire deal will boost resilience against price pressures Financial Times
May-19-18 04:10PM  Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching Benzinga
May-18-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
May-17-18 11:11AM  Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal Reuters
10:27AM  Biogen, Shire called out by FDA for gaming generic access rule American City Business Journals
08:32AM  Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal Reuters
08:10AM  FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal Reuters
May-16-18 02:01AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
May-15-18 07:00AM  Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness PR Newswire
02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
May-14-18 06:28PM  Takeda and Shire: A Pricey Marriage Motley Fool
05:37PM  Will athenahealth Be the Next Big Healthcare Deal? Motley Fool
10:51AM  Is There An Opportunity With Shire plcs (LON:SHP) 26% Undervaluation? Simply Wall St.
08:38AM  Is First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) a Hot ETF Right Now? Zacks
May-13-18 05:02AM  Value Stocks Investors Love Simply Wall St.
May-11-18 05:41AM  Iconic Genzyme building faces uncertain future after Shire-Takeda deal American City Business Journals
02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
May-10-18 04:05PM  Caladrius Biosciences Reports 2018 First Quarter Financial Results GlobeNewswire
07:21AM  Whisky and Apologies Aided Takeda's $62 Billion Gamble on Shire Bloomberg
12:05AM  Takeda Shareholders Should Come Around to Shire Bloomberg
May-09-18 02:31PM  SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Shire plc And Encourages Investors To Contact The Firm For Additional Information Business Wire
12:31PM  Shire Acq Inv Ireland Designated Activity Co -- Moody's reviews Shire's Baa3 ratings for upgrade Moody's
10:49AM  Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 Zacks
08:43AM  Takeda Debt Rating Cut by Moody's on $62 Billion Shire Deal Bloomberg
07:52AM  Takeda Pharmaceutical Company Limited -- Moody's downgrades Takeda Pharmaceutical to A2; places ratings on review for further downgrade Moody's
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
01:00AM  After $62 Billion Shire Win, Takeda CEO Faces More Headaches Bloomberg
12:15AM  [$$] Takeda Wins Battle for Shire With $62 Billion Deal The Wall Street Journal
May-08-18 03:56PM  After $62 Billion Shire Victory, Takeda CEO Faces Headaches Bloomberg
02:47PM  Takeda aims to boost rare disease profile with Shire deal, says R&D chief American City Business Journals
01:37PM  FTSE edges lower, but ends near 14-week high as oils drop offsets Shire stock rally MarketWatch
01:22PM  European stocks hold near 3-month high, but energy shares drop MarketWatch
01:04PM  Takeda-Shire Blockbuster Deal Comes With Blockbuster Risks Bloomberg
12:23PM  Takeda to Buy Shire for $62 Billion Investopedia
11:13AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Shire plc to Takeda Pharmaceutical Company Limited is Fair to Shareholders Business Wire
10:43AM  Valeant Upside, Shire Buyout Don't Rally Pharma Stocks
10:10AM  Evercore Claims Spot in Advisory Top Five on Takeda-Shire Role Bloomberg
09:51AM  Breaking Into the Top 10 Bloomberg
09:19AM  The Market In 5 Minutes: Schneiderman Resigns, Piwowar To Step Down, Spending Cuts And More Benzinga
09:14AM  Takeda Pharmaceuticals Clinches $62 Billion Acquisition Of Shire Investor's Business Daily
09:07AM  It's Official: Takeda Reaches Agreement To Acquire Shire For $62 Billion Benzinga
08:56AM  Irans Baited Breath, Shires Turning Japanese, And Comcast Gets Foxy With Disney Market Exclusive
08:55AM  Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on Reuters
08:38AM  Japan's Takeda clinches $62 billion deal to buy drugmaker Shire Reuters
08:37AM  Japan's Takeda clinches $62 bln Shire deal as pharma M&A rolls on Reuters
07:36AM  Japanese drug maker Takeda to buy Ireland's Shire Associated Press
06:47AM  Can Takeda Have Its $62 Billion Cake and Eat It? Bloomberg
06:27AM  Shire falls at last for £46bn in biggest UK takeover by Japan Evening Standard
06:17AM  Takeda finally lands £46bn takeover of Shire The Telegraph
06:07AM  Takeda Pharmaceutical Agrees $62.4 Billion Takeover of Shire
05:40AM  Takeda to buy Shire for $62B, creating states largest drugmaker American City Business Journals
04:57AM  Pound Has Limited Room to Gain From Takeda-Shire Deal Bloomberg
03:59AM  Asian Equities Extend Gains as China Trade Data Beats Estimates
02:20AM  Takeda Inks $62 Billion Deal to Buy Shire for Cash and Shares Bloomberg
02:20AM  Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire Bloomberg
02:17AM  Proposed Acquisition of Shire plc by Takeda Business Wire
12:30AM  Asian Stocks Climb; Iran Nuclear Deal, China Trade Data in Focus
May-07-18 08:41AM  Takeda Nears Deal to Buy Shire in Its Biggest Purchase Bloomberg
May-04-18 07:05AM  Blog Exposure - FDA Granted Fast Track Designation for REGENXBIO's RGX-121 Gene Therapy for Mucopolysaccharidosis Type II ACCESSWIRE
02:02AM  Shire plc : Rule 2.9 announcement GlobeNewswire
May-03-18 08:01AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
May-02-18 02:28PM  Shire plc : Form 8 (DD) - Thomas Dittrich GlobeNewswire
02:28PM  Shire plc : Form 8 (DD) - Flemming Ornskov GlobeNewswire
02:28PM  Shire plc : Director/PDMR Shareholding GlobeNewswire
May-01-18 10:46AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
07:01AM  Shire plc : Total voting rights GlobeNewswire
07:01AM  Shire plc : Form 8 (DD) - Flemming Ornskov GlobeNewswire
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Apr-30-18 02:51PM  MARKETS: Oil markets react to Iran latest, Apple stocks up ahead of earnings report, Walmart helps retails sector Yahoo Finance Video
08:43AM  Allergan CEO: large deal would be an unlikely outcome of review Reuters
Apr-27-18 11:16AM  Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong Zacks
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Apr-26-18 11:44PM  Edited Transcript of SHP.L earnings conference call or presentation 26-Apr-18 1:00pm GMT Thomson Reuters StreetEvents
01:02PM  Is Shire plcs (LON:SHP) Balance Sheet A Threat To Its Future? Simply Wall St.
10:39AM  Overshadowed by Takeda bid, Shire reports solid start to year Reuters
10:36AM  Shire: 1Q Earnings Snapshot Associated Press
10:00AM  [$$] Shire Sales Boost Profits, But No Comment on Takeda The Wall Street Journal
07:48AM  [$$] Shire Q1 sales rise 7% driven by immunology and new treatments Financial Times
07:27AM  Takeda's $64 Billion Offer Bolstered by Shire's Results Bloomberg
07:02AM  Shire plc : 1st Quarter Results GlobeNewswire
02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
12:07AM  [$$] Takeda Nears Shire Deal as Japanese Companies Chase Growth Overseas The Wall Street Journal
Apr-25-18 05:03PM  Shire Says It's Willing To Entertain $64 Billion Bid From Takeda Pharma Investor's Business Daily
01:18PM  Shire Acq Inv Ireland Designated Activity Co -- Moody's: An acquisition of Shire by Takeda could have positive or negative implications for Shire Moody's
12:38PM  Shire willing to back $64 billion Takeda bid, market signals doubts Reuters
12:13PM  FTSE 100 breaks 6-day win streak after rising bond yields spur selloff on Wall Street MarketWatch
11:10AM  Takeda's share price will make or break Shire deal, City says The Telegraph
10:00AM  Shire plc : Shire announces revised proposal and extension of PUSU deadline to 8 May 2018 GlobeNewswire
10:00AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
09:00AM  The Market In 5 Minutes: Treasury Yields, Twitter Beats, Takeda-Shire And More Benzinga
08:46AM  Shire willing to back $64 billion Takeda bid, market signals doubts Reuters
08:37AM  [$$] Takeda Nears Shire Deal as Japan Inc. Chases Growth Overseas The Wall Street Journal
08:28AM  [$$] Takeda shares tumble 9% after revised Shire takeover bid Financial Times
06:52AM  Drugmaker Takeda agrees to buy Shire for $64 billion Associated Press
06:47AM  Takeda plunges after Shire yields to £46bn fifth bid Evening Standard
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.